These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 24105606)

  • 21. Emerging approaches to target tumor metabolism.
    Ross SJ; Critchlow SE
    Curr Opin Pharmacol; 2014 Aug; 17():22-9. PubMed ID: 25048629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of genomics on personalized cancer medicine.
    Arteaga CL; Baselga J
    Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical cancer genomics: how soon is now?
    Taylor BS; Ladanyi M
    J Pathol; 2011 Jan; 223(2):318-26. PubMed ID: 21125684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.
    Cha S; Lee J; Shin JY; Kim JY; Sim SH; Keam B; Kim TM; Kim DW; Heo DS; Lee SH; Kim JI
    BMC Cancer; 2016 Feb; 16():170. PubMed ID: 26925973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic?
    Roukos DH
    Expert Rev Proteomics; 2012 Aug; 9(4):349-53. PubMed ID: 22967071
    [No Abstract]   [Full Text] [Related]  

  • 26. Biomarkers as molecular targets of drug interventions.
    Smith JJ; Dunn BK
    Semin Oncol Nurs; 2012 May; 28(2):109-15. PubMed ID: 22542318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer omics: from regulatory networks to clinical outcomes.
    Tang B; Hsu PY; Huang TH; Jin VX
    Cancer Lett; 2013 Nov; 340(2):277-83. PubMed ID: 23201140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Precision oncology: an overview.
    Garraway LA; Verweij J; Ballman KV
    J Clin Oncol; 2013 May; 31(15):1803-5. PubMed ID: 23589545
    [No Abstract]   [Full Text] [Related]  

  • 29. Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.
    Cruzalegui F
    Curr Opin Pharmacol; 2014 Aug; 17():iv-vi. PubMed ID: 25220882
    [No Abstract]   [Full Text] [Related]  

  • 30. Implementing precision medicine initiatives in the clinic: a new paradigm in drug development.
    Hollebecque A; Massard C; Soria JC
    Curr Opin Oncol; 2014 May; 26(3):340-6. PubMed ID: 24709975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Categorization of cancer through genomic complexity could guide research and management strategies.
    Horlings HM; Flanagan AM; Huntsman DG
    J Pathol; 2015 Aug; 236(4):397-402. PubMed ID: 25864408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systems biology analysis of autophagy in cancer therapy.
    Shi Z; Li CY; Zhao S; Yu Y; An N; Liu YX; Wu CF; Yue BS; Bao JK
    Cancer Lett; 2013 Sep; 337(2):149-60. PubMed ID: 23791881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional drug-gene interactions in lung cancer.
    Smida M; Nijman SM
    Expert Rev Mol Diagn; 2012 Apr; 12(3):291-302. PubMed ID: 22468819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opportunities and methods for studying alternative splicing in cancer with RNA-Seq.
    Feng H; Qin Z; Zhang X
    Cancer Lett; 2013 Nov; 340(2):179-91. PubMed ID: 23196057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The path to oncology drug target validation: an industry perspective.
    Cortés-Cros M; Schmelzle T; Stucke VM; Hofmann F
    Methods Mol Biol; 2013; 986():3-13. PubMed ID: 23436402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implications of intratumour heterogeneity for treatment stratification.
    Crockford A; Jamal-Hanjani M; Hicks J; Swanton C
    J Pathol; 2014 Jan; 232(2):264-73. PubMed ID: 24115146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New hopes in the fight against cancer: a special issue on targeted anti-cancer drug discovery and cell signaling.
    Cheng X
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):1-2. PubMed ID: 26578705
    [No Abstract]   [Full Text] [Related]  

  • 38. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer epigenetics as biomarkers of clinical significance.
    Panayiotidis MI
    Cancer Lett; 2014 Jan; 342(2):168-9. PubMed ID: 24183850
    [No Abstract]   [Full Text] [Related]  

  • 40. Personalized oncology: genomic screening in phase 1.
    Tuxen IV; Jønson L; Santoni-Rugiu E; Hasselby JP; Nielsen FC; Lassen U
    APMIS; 2014 Aug; 122(8):723-33. PubMed ID: 25046202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.